Section Arrow
Quote
PVLA.NASDAQ
- Palvella Therapeutics Inc
Quotes are at least 15-min delayed:2025/11/16 02:43 EST
Regular Hours
Last
 83.72
+3.22 (+4.00%)
Day High 
84.45 
Prev. Close
80.5 
1-M High
85.03 
Volume 
186.20K 
Bid
83.23
Ask
83.81
Day Low
78.99 
Open
79.06 
1-M Low
68.96 
Market Cap 
952.84M 
Currency USD 
P/E 13.7 
%Yield -- 
10-SMA 78.41 
20-SMA 76.29 
50-SMA 68.24 
52-W High 85.03 
52-W Low 11.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.53/-4.03
Enterprise Value
952.84M
Balance Sheet
Book Value Per Share
3.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
24.01
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 02:43 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.